Human Genome Epidemiology Literature Finder
Records 1 - 30 (of 38 Records) |
Query Trace: Lung Neoplasms and ABCG2[original query] |
---|
A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis. International journal of cancer. Journal international du cancer 2012 Dec 131 (12): 2920-8. Campa Daniele, Müller Phillip, Edler Lutz, Knoefel Lena, Barale Roberto, Heussel Claus P, Thomas Michael, Canzian Federico, Risch Ange |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity. Nagoya journal of medical science 2012 Feb 74 (1-2): 133-40. Tamura Mariko, Kondo Masashi, Horio Mihoko, Ando Maki, Saito Hiroshi, Yamamoto Masashi, Horio Yoshitsugu, Hasegawa Yoshino |
Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy. American journal of clinical oncology 2015 Jun 38 (3): 294-9. Kim Seok-Hyun, Kim Moon Jin, Cho Yu Ji, Jeong Yi Yeong, Kim Ho-Cheol, Lee Jong Duk, Hwang Young Sil, Kim In-Suk, Lee Suee, Oh Sung Yong, Ling Hui, Lee Gyeong-W |
Population pharmacokinetics/pharmacodynamics of erlotinib and pharmacogenomic analysis of plasma and cerebrospinal fluid drug concentrations in Japanese patients with non-small cell lung cancer. Clinical pharmacokinetics 2013 Jul 52 (7): 593-609. Fukudo Masahide, Ikemi Yasuaki, Togashi Yosuke, Masago Katsuhiro, Kim Young Hak, Mio Tadashi, Terada Tomohiro, Teramukai Satoshi, Mishima Michiaki, Inui Ken-Ichi, Katsura Toshi |
Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers. Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2013 Oct 67 (8): 801-6. Li Ning, Song Yuanyuan, Du Ping, Shen Yinchen, Yang Jianliang, Gui Lin, Wang Shuai, Wang Jianfei, Sun Yan, Han Xiaohong, Shi Yuank |
Association between the low-dose irinotecan regimen-induced occurrence of grade 4 neutropenia and genetic variants of UGT1A1 in patients with gynecological cancers. Oncology letters 2014 Jun 7 (6): 2035-2040. Moriya Hiroyuki, Saito Katsuhiko, Helsby Nuala, Sugino Shigekazu, Yamakage Michiaki, Sawaguchi Takeru, Takasaki Masahiko, Kato Hidenori, Kurosawa Naho |
Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer. Pharmacogenomics 2014 15 (12): 1565-74. Lamba Jatinder Kaur, Fridley Brooke L, Ghosh Taraswi M, Yu Qing, Mehta Gaurav, Gupta Pank |
Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients. Cancer cell international 2015 15 43. Chen Xueqin, Chen Dadong, Yang Shaoyu, Ma Ruobing, Pan Yuelong, Li Xin, Ma Shengl |
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer. Clinical lung cancer 2015 Jul 16 (4): 274-81. Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato |
A potentially functional polymorphism in ABCG2 predicts clinical outcome of non-small cell lung cancer in a Chinese population. The pharmacogenomics journal 2016 Mar . Sun J, Zhu M, Shen W, Wang C, Dai J, Xu L, Jin G, Hu Z, Ma H, Shen |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76. Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu |
Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients. Oncotarget 2017 Aug 8 (34): 57528-57536. Kim Lucia, Saieg Mauro, Di Maio Massimo, Gallo Ciro, Butts Charles, Ciardiello Fortunato, Feld Ronald, Cheng Dengxiao, Gebbia Vittorio, Burgio Marco Angelo, Alam Yasmin, Signoriello Simona, Rossi Antonio, Leighl Natasha, Maione Paolo, Morabito Alessandro, Liu Geoffrey, Tsao Ming-Sound, Perrone Francesco, Gridelli Cesa |
Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients. Scientific reports 2017 Jul 7 (1): 5082. Cui Jia-Jia, Wang Lei-Yun, Zhu Tao, Gong Wei-Jing, Zhou Hong-Hao, Liu Zhao-Qian, Yin Ji- |
Discovering novel SNPs that are correlated with patient outcome in a Singaporean cancer patient cohort treated with gemcitabine-based chemotherapy. BMC cancer 2018 May 18 (1): 555. Limviphuvadh Vachiranee, Tan Chee Seng, Konishi Fumikazu, Jenjaroenpun Piroon, Xiang Joy Shengnan, Kremenska Yuliya, Mu Yar Soe, Syn Nicholas, Lee Soo Chin, Soo Ross A, Eisenhaber Frank, Maurer-Stroh Sebastian, Yong Wei Pe |
Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis. OncoTargets and therapy 2018 11 665-675. Tang Lina, Zhang Chunling, He Hairong, Pan Zhenyu, Fan Di, He Yinli, You Haisheng, Li Yuanj |
Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters. Biological & pharmaceutical bulletin 2018 41 (1): 47-56. Endo-Tsukude Chihiro, Sasaki Ji-Ichiro, Saeki Sho, Iwamoto Norihiro, Inaba Megumi, Ushijima Sunao, Kishi Hiroto, Fujii Shinji, Semba Hiroshi, Kashiwabara Kosuke, Tsubata Yukari, Hayashi Mitsuhiro, Kai Yuki, Saito Hideyuki, Isobe Takeshi, Kohrogi Hirotsugu, Hamada Akino |
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2019 7 134 1-6. Hayashi Hideki, Iihara Hirotoshi, Hirose Chiemi, Fukuda Yoshihisa, Kitahora Mika, Kaito Daizo, Yanase Komei, Endo Junki, Ohno Yasushi, Suzuki Akio, Sugiyama Tadas |
ABCG2 C421A polymorphisms affect exposure of the epidermal growth factor receptor inhibitor gefitinib. Investigational new drugs 2020 May . Sakamoto Sho, Sato Kazuhiro, Takita Yuri, Izumiya Yuka, Kumagai Naho, Sudo Kazuhisa, Hasegawa Yukiyasu, Yokota Hayato, Akamine Yumiko, Okuda Yuji, Asano Mariko, Takeda Masahide, Sano Masaaki, Miura Masatomo, Nakayama Katsutos |
Association of Genetic Polymorphisms With Afatinib-induced Diarrhoea. In vivo (Athens, Greece) 0 34 (3): 1415-1419. Sogawa Rintaro, Nakashima Chiho, Nakamura Tomomi, Takeuchi Koji, Kimura Sakiko, Komiya Kazutoshi, Narisawa Yutaka, Kimura Shinya, Sueoka-Aragane Nao |
A meta-analysis of ABCG2 gene polymorphism and non-small cell lung cancer outcomes. Genetics and molecular biology 2020 3 42 (4): e20180234. Fu Lei, Wang Rong, Yin Ling, Shang Xiaopu, Zhang Runtong, Zhang Pengj |
The analysis of pharmacokinetic and pharmacogenomic impact on gefitinib efficacy in advanced non-small cell lung cancer patients: results from a prospective cohort study. Annals of translational medicine 2019 Dec 7 (24): 806. Ma Yuxiang, Xin Shuang, Lin Qingguang, Zhuang Wei, Zhao Yuanyuan, Zhu Xia, Zhao Hongyun, Huang Min, Xun Xu, Yang Yunpeng, Fang Wenfeng, Zhang Li, Wang Xuedi |
A pharmacogenetics study of platinum-based chemotherapy in lung cancer: ABCG2 polymorphism and its genetic interaction with SLC31A1 are associated with response and survival. Journal of Cancer 2021 2 12 (5): 1270-1283. Wang Liyan, Sun Chang, Li Xiangnan, Mao Chenxue, Qian Ji, Wang Jiucun, Wu Junjie, Li Qiang, Bai Chunxue, Han Baohui, Gao Zhiqiang, Xu Jibin, Yin Jiye, Liu Zhaoqian, Lu Daru, Jin Li, Wang Haiji |
Effects of CYP3A4/5 and ABC transporter polymorphisms on osimertinib plasma concentrations in Japanese patients with non-small cell lung cancer. Investigational new drugs 2022 9 40 (6): 1254-1262. Yokota Hayato, Sato Kazuhiro, Sakamoto Sho, Okuda Yuji, Fukuda Natsuki, Asano Mariko, Takeda Masahide, Nakayama Katsutoshi, Miura Masato |
The Association Between Genetic Polymorphisms of Transporter Genes and Prognosis of Platinum-Based Chemotherapy in Lung Cancer Patients. Pharmacogenomics and personalized medicine 2022 15 817-825. He Jia, Wang Zhan, Zou Ting, Wang Ying, Li Xiang-Ping, Chen Ju |
Genetic variations in ABC transporter genes as a predictive biomarker for toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy. Journal of biochemical and molecular toxicology 2022 12 e23269. Sharma Parul, Singh Navneet, Sharma Siddhar |
Pharmacokinetics of gefitinib in elderly patients with EGFR-mutated advanced non-small cell lung cancer: a prospective study. BMC pulmonary medicine 2022 11 22 (1): 454. Nio Yuta, Ishida Hiroo, Matsumoto Natsumi, Kusumoto Sojiro, Kubota Yutaro, Tsunoda Takuya, Sasaki Yasutsuna, Fujita Ken-Ic |
Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy. The journal of gene medicine 2022 10 25 (1): e3460. Sharma Parul, Singh Navneet, Sharma Siddhar |
Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer. EClinicalMedicine 2023 5 59 101955. G D Marijn Veerman, Rene J Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J van der Wekken, Idris Bahce, Lizza E L Hendriks, Sander Croes, Christi M J Steendam, Evert de Jonge, Stijn L W Koolen, Neeltje Steeghs, Ron H N van Schaik, Egbert F Smit, Anne-Marie C Dingemans, Alwin D R Huitema, Ron H J Mathijss |
CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients. Frontiers in pharmacology 2023 11 14 1222435. Teerapat Majam, Chonlaphat Sukasem, Thanyanan Reungwetwattana, Phichai Chansriwong, Chalirmporn Atasilp, Narumol Trachu, Thanaporn Thamrongjirapat, Rattanaporn Sukprasong, Jennis Meanwattha |
Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study. Investigational new drugs 2023 1 . Ishikawa Emi, Yokoyama Yuta, Chishima Haruna, Kasai Hidefumi, Kuniyoshi Ouki, Kimura Motonori, Hakamata Jun, Nakada Hideo, Suehiro Naoya, Nakaya Naoki, Nakajima Hideo, Ikemura Shinnosuke, Kawada Ichiro, Yasuda Hiroyuki, Terai Hideki, Jibiki Aya, Kawazoe Hitoshi, Soejima Kenzo, Muramatsu Hiroshi, Suzuki Sayo, Nakamura Tomono |
- Page last reviewed:Feb 1, 2024
- Content source: